Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 3.3%

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) traded down 3.3% on Tuesday . The stock traded as low as $9.64 and last traded at $9.67. 22,270 shares changed hands during trading, a decline of 94% from the average session volume of 348,044 shares. The stock had previously closed at $10.00.

Analyst Ratings Changes

Separately, BMO Capital Markets restated an “outperform” rating and issued a $15.00 price target on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Centessa Pharmaceuticals Stock Performance

The stock’s 50-day moving average price is $10.90 and its 200-day moving average price is $8.51. The company has a current ratio of 8.00, a quick ratio of 8.00 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $895.77 million, a P/E ratio of -5.69 and a beta of 1.38.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. The firm had revenue of $6.85 million during the quarter. As a group, equities analysts expect that Centessa Pharmaceuticals plc will post -1.83 EPS for the current year.

Insider Activity at Centessa Pharmaceuticals

In related news, SVP Harris Rotman sold 4,267 shares of Centessa Pharmaceuticals stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.10, for a total value of $34,562.70. Following the sale, the senior vice president now directly owns 62,625 shares in the company, valued at approximately $507,262.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 51,160 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $11.88, for a total transaction of $607,780.80. Following the transaction, the insider now owns 71,525 shares of the company’s stock, valued at approximately $849,717. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Harris Rotman sold 4,267 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.10, for a total transaction of $34,562.70. Following the transaction, the senior vice president now directly owns 62,625 shares in the company, valued at approximately $507,262.50. The disclosure for this sale can be found here. 11.54% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its stake in shares of Centessa Pharmaceuticals by 371.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock worth $51,000 after purchasing an additional 5,037 shares during the last quarter. Quarry LP acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth approximately $48,000. Jump Financial LLC acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth approximately $114,000. Trexquant Investment LP acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth approximately $114,000. Finally, Rathbones Group PLC acquired a new position in shares of Centessa Pharmaceuticals in the 3rd quarter worth approximately $203,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.